# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Muhammad Ali (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX001-SYN-TD
- Date: 1996-09-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Moreau, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month Parkinson's disease review. **S**

## History of present illness

Mr. Ali returns six months after his first visit. He continues carbidopa-levodopa one and a half tablets three times a day before meals, with phone alarms, and has noticed no wearing-off, involuntary movements, or lightheadedness. He finished physical therapy and keeps up about 180 minutes a week of walking, stationary cycling, and balance exercises. He practices his voice exercises daily. He has had no falls. When asked about impulse control today, he reports no new urges to gamble, shop, or eat and no compulsive hobbies. He has not yet seen a dentist. **S**

| Element | Detail |
|---|---|
| Medicines | Levodopa 150 mg three times daily before meals; no side effects |
| Motor complications | None |
| Exercise | About 180 minutes a week |
| Falls | None in six months |
| Impulse control | No new urges or compulsive behaviors |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No lightheadedness on standing or fainting |
| Gastrointestinal | Negative | No constipation, nausea, or trouble swallowing |
| Neurological | Positive | Mild slowness and right-hand tremor, unchanged since the spring |
| Psychiatric | Negative | Mood good; no hallucinations or impulse-control problems |

4 systems reviewed. **S**

## Current medications

- Carbidopa-levodopa 25/100 mg oral tablet, one and a half tablets by mouth three times daily, 30 minutes before meals **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 101 kg; BMI 27.7 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Alert and engaged; voice clear in conversation |
| Cardiovascular | Regular rhythm at 70 per minute. Blood pressure 128/80 mmHg supine and 120/78 mmHg after 3 minutes standing, without symptoms; no orthostatic hypotension |
| Neurological | On state: MDS-UPDRS Part III 24; Hoehn and Yahr stage 2.5; no dyskinesia |
| Gait | Recovers after two steps on the pull test; Timed Up and Go 11 seconds |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Parkinson's disease, Hoehn and Yahr stage 2.5** (G20.A1). Stable: MDS-UPDRS Part III 24, no motor complications, no orthostatic hypotension, and no falls in six months. Impulse-control screen negative. **S**
   - Continue carbidopa-levodopa 150 mg three times daily before meals.
   - Continue exercise at 150 minutes a week or more.
   - Dental examination to be arranged at the preventive visit.
   - Yearly movement disorders review in the spring, with the genetic testing decision.
2. **Hypokinetic dysarthria with soft speech** (R47.1). Gains from speech therapy maintained. **S**
   - Continue daily voice exercises.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | MDS-UPDRS Parts III and IV and Hoehn and Yahr stage | Every visit | Completed today | Part III 24, unchanged; Hoehn and Yahr 2.5; Part IV: no motor complications |
| Examination | Orthostatic blood pressure, supine and after 3 minutes standing | Every visit while on dopaminergic treatment | Completed today | 128/80 mmHg supine and 120/78 mmHg at 3 minutes standing; no orthostatic hypotension |
| Medication safety | Dopaminergic regimen review for wearing-off, dyskinesia, and on-off | Every visit | Completed today | No wearing-off or dyskinesia; no change |
| Medication safety | Avoidance of dopamine-blocking drugs | Every visit | Completed today | No dopamine-blocking drugs |
| Medication safety | Medication side effects and adherence | Every visit | Completed today | No side effects or missed doses |
| Examination | Fall query and fall-risk assessment (Timed Up and Go, pull test) | Every visit | Completed today | No falls in six months; Timed Up and Go 11 seconds |
| Survey | Psychotic symptoms (hallucinations, delusions) | Every visit | Completed today | None |
| Survey | Impulse-control screen (QUIP-RS) | Every visit; mandatory on a dopamine agonist | Completed today | Negative; the screen missed at three months was done today |
| Self-management | Exercise counseling: aerobic, resistance, and balance, at least 150 minutes a week | Every visit | Completed today | About 180 minutes a week |
| Self-management | Advance care planning and goals of care | At diagnosis and at least yearly | Due | At the preventive visit next month |
| Examination | Diagnosis review against the MDS clinical diagnostic criteria | Yearly | Up to date | Confirmed by neurology six months ago; next review in the spring |
| Survey | Cognitive screen (MoCA) | At least yearly | Up to date | MoCA 27 of 30 seven months ago |
| Survey | Depression, anxiety, and apathy (PHQ-9) | At least yearly | Up to date | PHQ-9 3 seven months ago; mood good today; depression screen at the preventive visit |
| Survey | Sleep: REM sleep behavior disorder questionnaire, Epworth Sleepiness Scale, insomnia, restless legs | At least yearly | Up to date | No dream enactment or daytime sleepiness |
| Survey | Autonomic symptoms: constipation, urinary, sexual, sweating, drooling | At least yearly | Up to date | No autonomic symptoms |
| Survey | Swallowing screen (EAT-10) | At least yearly | Up to date | No choking or coughing with meals; EAT-10 due at the first visit next year |
| Examination | Speech and voice loudness | Yearly; speech therapy for speech change | Up to date | Gains maintained with daily practice |
| Referral | Physical, occupational, and speech therapy | At diagnosis, then reassessed yearly | Up to date | Physical therapy and speech therapy completed; reassess yearly |
| Laboratory | Genetic testing with counseling | Once, offered to every person with Parkinson's disease | Due | Decision at the yearly neurology review |
| Examination | Dental and oral examination | Every 6 months | Deferred | No dental examination in the six months since the first visit, a deviation from the protocol. He has no drooling, mouth pain, or chewing problems, so no harm is evident. Corrective action: a dental appointment is to be arranged at the preventive visit next month |
| Examination | Driving safety | Yearly or with a motor or cognitive change | Up to date | No change; review at the first visit next year |
| Self-management | Vaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap) | Yearly, per the CDC schedule | Due | Influenza, pneumococcal, and zoster vaccines at the preventive visit next month |
| Laboratory | Routine laboratory monitoring | Not required for Parkinson's disease surveillance | Not indicated | The CMID monograph calls for no routine laboratory tests; baseline blood count, chemistry, vitamin B12, and TSH were normal at the first visit |
| Imaging | Brain MRI | If atypical parkinsonism features appear | Not indicated | No atypical features; examination stable |
| Imaging | Polysomnography for REM sleep behavior disorder | If REM sleep behavior disorder treatment is considered | Not indicated | No dream enactment |
| Medication safety | AGS Beers Criteria medication review | Yearly from age 65 | Not indicated | He is 54 |
| Examination | Deep brain stimulation programming review | Every 6 to 12 months after implantation | Not indicated | No deep brain stimulator |

## Goal progress

- Less slowness of movement after a levodopa adjustment, without dyskinesia or orthostatic hypotension, by the three-month review. Outcome by 1996-06-09: MDS-UPDRS Part III fell from 30 to 24; no dyskinesia; no orthostatic hypotension. **S**
- Complete a four-week intensive speech therapy course and keep up daily voice practice. Outcome by 1996-06-09: LSVT LOUD course completed; easier to hear in conversation; daily home practice continues. **S**
- No falls through the six-month review, with at least 150 minutes a week of exercise including balance work. Outcome by 1996-09-08: No falls; Timed Up and Go improved from 13 to 11 seconds; exercising about 180 minutes a week. **S**
- Name a health care agent and record his goals of care by the preventive visit. In progress; target 1996-10-06. **S**

## Guideline basis

- Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021), American Academy of Neurology (Neurology)
- MDS clinical diagnostic criteria for Parkinson's disease (2015), International Parkinson and Movement Disorder Society (Movement Disorders)
- The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension (2017), American Autonomic Society and National Parkinson Foundation (Journal of Neurology)
- CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026), Aether Forge

## Follow-up

- Periodic preventive visit in four weeks, with vaccines, advance care planning, and the dental appointment. Quarterly Parkinson's disease review in three months. **S**
- Next scheduled visit 1996-10-06: periodic adult preventive visit. **S**
